AbbVie is currently addressing serious health ... Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil. Abbott's presence in these high-growth ...

New Delhi, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The global pharma & biotech CRM software market was valued at US$ 7.21 billion IN 2024 and is projected to reach US$ 20.0 by 2033 at a CAGR of 15.2% during ...

While pediatric atopic dermatitis cases rose globally between 2000 and 2021, the prevalence rate dropped, showing important ...

The global ophthalmic sprays market, valued at USD 343 million in 2023, is projected to experience exponential growth, ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

North Chicago, Illinois-based AbbVie Inc. (ABBV) focuses on creating medicines and solutions that address complex health issues and enhance people's lives through its core therapeutic areas ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.